3.81
+8.24%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Recursion Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Recursion Pharmaceuticals is based in Salt Lake City, Utah and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RXRX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $74.7m and a net loss of $644.8m. At that date it held total assets of $1.47bn and shareholders' equity of $1.13bn. By business, Operating revenue brought in 99.4% of revenue, followed by Grant revenue at 0.6%. By region, United States accounted for 52.7%, followed by United Kingdom at 47.3%.
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. All of our technologies are designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Historically, it has taken over ten years and an average capitalized R&D cost of approximately $2-3.5 billion to move a drug discovery project from early discovery to an approved therapeutic, with less than 4% of drug discovery programs initiated resulting in an approved medicine.1,2,3,4,5,6 Today, we are working to transform the traditional high-attrition, “V-shaped” discovery funnel by pivoting to a ‘T-shaped’ model. By leveraging advanced computational tools across biology, chemistry and clinical development, we aim to rapidly narrow a broad set of potential medicines to the candidates with the highest probabilities of success, with the goal to move programs through development more efficiently and with less attrition.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Apr 2021
- Employees
- 600
- Website
- recursion.com ↗
- Head office
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Robert HershbergIndependent Chairman of the Board$316,480
- Dr. Christopher GibsonPresident, Chief Executive Officer, Co-Founder, Director, since 2013$8.5m
- Mr. Ben TaylorChief Financial Officer, President of Recursion UK$8.2m
- Dr. Najat KhanDirector, Chief Research and Development Officer, Chief Commercial Officer, since 2024$9.2m
- Mr. Zachary BogueIndependent Director$21,252
- Dr. Blake BorgesonIndependent Director, since 2013$294,982
- Dr. Namandje BumpusIndependent Director
- Mr. Zavain DarIndependent Director$304,227
- Dr. Dean LiIndependent Director, since 2013$296,730
- Dr. Franziska MichorIndependent Director$753,107
- Ms. Elaine SunIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 75
- Social
- 99
- Governance
- 55
- Direct emissions (scope 1)
- 269 t
- Energy emissions (scope 2)
- 980 t
- Women in the workforce
- 43%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Recursion Pharmaceuticals employs 600 employees in Salt Lake City for biotechnology innovation.
- Recursion Operating System (OS) maps trillions of biological relationships in the Recursion Data Universe.
- Clinical programs REC-994 and REC-2282 target cerebral cavernous malformations and other conditions.
Weaknesses
- Recursion's IPO on April 16, 2021, marks a recent market entry with limited historical data.
- The company's focus on automation and AI may require significant ongoing investment.
- Recursion's clinical programs are still in early stages with no approved drugs yet.
Opportunities
- Recursion's platform could expand into new therapeutic areas like oncology or neurology.
- The biotechnology sector in the US offers growth potential for clinical-stage companies.
- Salt Lake City's emerging biotech hub supports talent acquisition and innovation.
Threats
- Competition in the biotechnology sector intensifies with new entrants and established firms.
- Regulatory hurdles may delay clinical trials and drug approvals for Recursion's programs.
- Economic downturns could reduce funding for biotech startups and clinical-stage companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.